Daily Archives: 24th March 2018

Ardelyx signs termination agreement with AstraZeneca.

Ardelyx is now able to accelerate the clinical development of tenapanor to meet the requirements of two underserved patient populations. We are grateful for the substantial expenditure that AstraZeneca has made in the NHE3 program, and we’ve been fortunate to have them as somebody,’ Mr. Raab added. In a separate press release, Ardelyx announced today a new product candidate, RDX022, for which it will be pursuing a 505b regulatory pathway in the United States. Ardelyx is certainly developing RDX022 for the treatment of elevated potassium, or hyperkalemia. Ardelyx expects to initiate scientific trials with RDX022 in mid-2015. Ardelyx also announced today that it offers entered into an agreement to sell shares of common share and warrants to get common share for the aggregate gross proceeds of approximately $77.8 million in a private placement. Continue reading